IDEAS home Printed from https://ideas.repec.org/a/bla/biomet/v69y2013i3p673-682.html
   My bibliography  Save this article

Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes

Author

Listed:
  • Peter F. Thall
  • Hoang Q. Nguyen
  • Thomas M. Braun
  • Muzaffar H. Qazilbash

Abstract

No abstract is available for this item.

Suggested Citation

  • Peter F. Thall & Hoang Q. Nguyen & Thomas M. Braun & Muzaffar H. Qazilbash, 2013. "Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes," Biometrics, The International Biometric Society, vol. 69(3), pages 673-682, September.
  • Handle: RePEc:bla:biomet:v:69:y:2013:i:3:p:673-682
    DOI: 10.1111/biom.12065
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1111/biom.12065
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.1111/biom.12065?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Peter F. Thall & Aniko Szabo & Hoang Q. Nguyen & Catherine M. Amlie-Lefond & Osama O. Zaidat, 2011. "Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion," Biometrics, The International Biometric Society, vol. 67(4), pages 1638-1646, December.
    2. Peter F. Thall & John D. Cook, 2004. "Dose-Finding Based on Efficacy–Toxicity Trade-Offs," Biometrics, The International Biometric Society, vol. 60(3), pages 684-693, September.
    3. Ying Kuen Cheung & Rick Chappell, 2000. "Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities," Biometrics, The International Biometric Society, vol. 56(4), pages 1177-1182, December.
    4. Ying Yuan & Guosheng Yin, 2009. "Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(5), pages 719-736, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Emma Gerard & Sarah Zohar & Hoai‐Thu Thai & Christelle Lorenzato & Marie‐Karelle Riviere & Moreno Ursino, 2022. "Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics," Biometrics, The International Biometric Society, vol. 78(1), pages 300-312, March.
    2. Peter F. Thall & Hoang Q. Nguyen & Ralph G. Zinner, 2017. "Parametric dose standardization for optimizing two-agent combinations in a phase I–II trial with ordinal outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 66(1), pages 201-224, January.
    3. Thomas A. Murray & Peter F. Thall & Ying Yuan & Sarah McAvoy & Daniel R. Gomez, 2017. "Robust Treatment Comparison Based on Utilities of Semi-Competing Risks in Non-Small-Cell Lung Cancer," Journal of the American Statistical Association, Taylor & Francis Journals, vol. 112(517), pages 11-23, January.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Peter F. Thall & Aniko Szabo & Hoang Q. Nguyen & Catherine M. Amlie-Lefond & Osama O. Zaidat, 2011. "Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion," Biometrics, The International Biometric Society, vol. 67(4), pages 1638-1646, December.
    2. Nadine Houede & Peter F. Thall & Hoang Nguyen & Xavier Paoletti & Andrew Kramar, 2010. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials," Biometrics, The International Biometric Society, vol. 66(2), pages 532-540, June.
    3. Laura Deldossi & Silvia Angela Osmetti & Chiara Tommasi, 2019. "Optimal design to discriminate between rival copula models for a bivariate binary response," TEST: An Official Journal of the Spanish Society of Statistics and Operations Research, Springer;Sociedad de Estadística e Investigación Operativa, vol. 28(1), pages 147-165, March.
    4. Peter F. Thall & Hoang Q. Nguyen & Ralph G. Zinner, 2017. "Parametric dose standardization for optimizing two-agent combinations in a phase I–II trial with ordinal outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 66(1), pages 201-224, January.
    5. Ying Yuan & Guosheng Yin, 2009. "Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(5), pages 719-736, December.
    6. Erica Brittain & Dean Follmann & Song Yang, 2008. "Dynamic Comparison of Kaplan–Meier Proportions: Monitoring a Randomized Clinical Trial with a Long-Term Binary Endpoint," Biometrics, The International Biometric Society, vol. 64(1), pages 189-197, March.
    7. Yifei Zhang & Sha Cao & Chi Zhang & Ick Hoon Jin & Yong Zang, 2021. "A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes," Biometrics, The International Biometric Society, vol. 77(3), pages 796-808, September.
    8. Thomas A. Murray & Peter F. Thall & Ying Yuan & Sarah McAvoy & Daniel R. Gomez, 2017. "Robust Treatment Comparison Based on Utilities of Semi-Competing Risks in Non-Small-Cell Lung Cancer," Journal of the American Statistical Association, Taylor & Francis Journals, vol. 112(517), pages 11-23, January.
    9. Thomas M. Braun, 2018. "Motivating sample sizes in adaptive Phase I trials via Bayesian posterior credible intervals," Biometrics, The International Biometric Society, vol. 74(3), pages 1065-1071, September.
    10. Beibei Guo & Ying Yuan, 2023. "DROID: dose‐ranging approach to optimizing dose in oncology drug development," Biometrics, The International Biometric Society, vol. 79(4), pages 2907-2919, December.
    11. Chunyan Cai & Ying Yuan & Yuan Ji, 2014. "A Bayesian dose finding design for oncology clinical trials of combinational biological agents," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 63(1), pages 159-173, January.
    12. Changying A. Liu & Thomas M. Braun, 2009. "Parametric non‐mixture cure models for schedule finding of therapeutic agents," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(2), pages 225-236, May.
    13. B. Nebiyou Bekele & Yisheng Li & Yuan Ji, 2010. "Risk-Group-Specific Dose Finding Based on an Average Toxicity Score," Biometrics, The International Biometric Society, vol. 66(2), pages 541-548, June.
    14. Sergei Leonov & Bahjat Qaqish, 2020. "Correlated endpoints: simulation, modeling, and extreme correlations," Statistical Papers, Springer, vol. 61(2), pages 741-766, April.
    15. Ying Kuen Cheung & Peter F. Thall, 2002. "Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials," Biometrics, The International Biometric Society, vol. 58(1), pages 89-97, March.
    16. B. Nebiyou Bekele & Yu Shen, 2005. "A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-Finding Trial," Biometrics, The International Biometric Society, vol. 61(2), pages 343-354, June.
    17. Alessandra Giovagnoli, 2021. "The Bayesian Design of Adaptive Clinical Trials," IJERPH, MDPI, vol. 18(2), pages 1-15, January.
    18. Anastasia Ivanova & Se Hee Kim, 2009. "Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach," Biometrics, The International Biometric Society, vol. 65(1), pages 307-315, March.
    19. Ying Kuen Cheung, 2014. "Simple benchmark for complex dose finding studies," Biometrics, The International Biometric Society, vol. 70(2), pages 389-397, June.
    20. Ying Kuen Cheung, 2002. "On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance," Biometrics, The International Biometric Society, vol. 58(1), pages 237-240, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:biomet:v:69:y:2013:i:3:p:673-682. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0006-341X .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.